First-line TQB2450 plus anlotinib combined with paclitaxel and cisplatin for advanced esophageal squamous cell carcinoma (ESCC): Update results of a multi-center phase II trial.

被引：0
|
作者：
Wang, Junsheng
Li, Ning
Guo, Yanzhen
Cheng, Yufeng
Li, Baosheng
Luo, Suxia
机构：
[1] Anyang Canc Hosp, Dept Med Oncol, Anyang, Peoples R China
[2] Zhengzhou Univ, Affiliated Canc Hosp, Henan Canc Hosp, Dept Med Oncol, Zhengzhou, Peoples R China
[3] Henan Univ Sci & Technol, Affiliated Hosp 1, Luoyang, Peoples R China
[4] Qilu Hosp Shandong Univ, Jinan, Peoples R China
[5] Shandong Canc Hosp & Inst, Jinan, Peoples R China
[6] Henan Canc Hosp, Zhengzhou, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16011
引用
收藏
页数：1
相关论文
共 50 条
  • [1] TQB2450 plus anlotinib combined with paclitaxel and cisplatin as first-line treatment of advanced esophageal squamous cell carcinoma (ESCC): Update results of a single-arm, multicenter phase. trial
    Wang, Junsheng
    Li, Ning
    Guo, Yanzhen
    Cheng, Yufeng
    Li, Baosheng
    Luo, Su-xia
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial.
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [3] Update results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase II clinical trial
    Hong, G.
    Meng, X.
    Yang, X.
    Zhang, Z. Y.
    Xia, J.
    Chen, Y-F.
    Wu, T.
    Shan, Z.
    Fan, Q.
    Wang, F.
    ANNALS OF ONCOLOGY, 2023, 34 : S861 - S861
  • [4] A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
    Ning Li
    Tao Wu
    Yong-Gui Hong
    Yan-Zhen Guo
    Yu-Feng Cheng
    Yi-Jie Ma
    Liang-Yu Bie
    Dong-Hai Cui
    Xiao-Hui Gao
    Bing-Xu Tan
    Bao-Sheng Li
    Su-Xia Luo
    Jun-Sheng Wang
    BMC Medicine, 20
  • [5] A multi-center, single-arm, phase II study of anlotinib plus paclitaxel and cisplatin as the first-line therapy of recurrent/advanced esophageal squamous cell carcinoma
    Li, Ning
    Wu, Tao
    Hong, Yong-Gui
    Guo, Yan-Zhen
    Cheng, Yu-Feng
    Ma, Yi-Jie
    Bie, Liang-Yu
    Cui, Dong-Hai
    Gao, Xiao-Hui
    Tan, Bing-Xu
    Li, Bao-Sheng
    Luo, Su-Xia
    Wang, Jun-Sheng
    BMC MEDICINE, 2022, 20 (01)
  • [6] Anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial.
    Yang, Xiuli
    Meng, Xiangrui
    Hong, Yong-Gui
    Zhang, Zhiye
    Xia, Jin
    Wu, Tao
    Chen, Yunfang
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 377 - 377
  • [7] Update results of paclitaxel and cisplatin in combination with anlotinib as first-line regimen for advanced esophageal squamous cell carcinoma (ESCC): A multicenter, single-arm, open-label phase II clinical trial.
    Wang Junsheng
    Luo Suxia
    Li Ning
    Wu Tao
    Hong Yonggui
    Guo Yanzhen
    Cheng Yufeng
    Li Baosheng
    Tan Bingxu
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [8] Update results of anlotinib combined with penpulimab and nab-paclitaxel as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, open-label phase II clinical trial.
    Chang, Zhiwei
    Liu, Xiao-Lei
    Yu, Dan-Dan
    Han, Hui-Qiong
    He, Jian
    Wang, Rui-Rui
    Jia, Yong-Xu
    Yan, Jie
    Qin, Yanru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Update results of anlotinib plus TQB2450 (PD-L1 blockade) combined with nab-paclitaxel and cisplatin as first-line treatment for advanced biliary tract cancer: A single-arm, open-label phase II clinical trial.
    Guo, Wen-Zhi
    Li, Lu-Hao
    Qiao, Shishi
    Li, Ren-Feng
    Zhang, Weijie
    He, Wei
    Su, Chang
    Pan, Jie
    Jin, Shui-Ling
    Zong, Hong
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [10] Updated results of anlotinib combined with TQB2450 (PD-L1 blockade) as first-line treatment for advanced esophageal squamous cell carcinoma (ESCC): A single-arm, multicenter, open-label phase. clinical trial
    Zhang, Zhiye
    Meng, Xiangrui
    Yang, Xiuli
    Hong, Yong-Gui
    Xia, Jin
    Chen, Yunfang
    Wu, Tao
    Shan, Zheng-Zheng
    Fan, Qingxia
    Wang, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345